JAKARTA - PT Bio Farma (Persero) held a strategic meeting with the Indonesian Food and Drug Supervisory Agency (BPOM RI) at the BPOM RI Office, Jakarta, on April 27, 2026. This meeting is part of strengthening synergy between regulators and industry in supporting national health resilience and improving the competitiveness of Indonesian vaccine and biological products at the global level.
The audience was attended by the Head of BPOM RI, Taruna Ikrar, and his staff, as well as the President Director of Bio Farma, Shadiq Akasya, along with the Board of Directors of Bio Farma.
One of the main focuses of this meeting is support for strengthening the role of BPOM RI as a WHO Listed Authority (WLA). This status is an important recognition from the World Health Organization (WHO) of a country's regulatory system that has met international standards. For Indonesia, this achievement is a strategic momentum to strengthen global confidence in the national drug and vaccine surveillance system.
In this meeting, both parties discussed a number of strategic agendas, including strengthening collaboration in the development and supervision of vaccine products and biological products, synergy in the registration and certification process of products, and opportunities for cooperation to increase the competitiveness of the national life science industry in the global market.
Bio Farma President Director, Shadiq Akasya, expressed his appreciation for this achievement as an important foundation in increasing global confidence in Indonesian health products.
"We express our appreciation for the achievement of BPOM RI as a WHO Listed Authority. This recognition is not only a source of pride for regulators, but also an important capital for the national industry to be increasingly trusted in the global market. For Bio Farma, synergy with BPOM RI is an important part in ensuring Indonesian vaccine and biological products continue to meet internationally recognized standards of safety, quality, and efficacy," said Shadiq.
As a life science BUMN in the Danantara ecosystem, Bio Farma has a strategic role in supporting the transformation of the national health industry. This role is realized through strengthening production capacity, product portfolio development, expanding global cooperation, and contributing to Indonesia's health independence and resilience.
"As part of the Danantara ecosystem, Bio Farma is committed to continue strengthening its role as a strategic SOE that is not only oriented towards business performance, but also towards the benefits of society, the nation, and global health. In the future, we will continue to strengthen collaboration with BPOM RI and other stakeholders so that Indonesian health products are more competitive, trusted, and provide wider benefits," added Shadiq.
The strengthening of the regulatory system through the WLA status is expected to accelerate the registration process of Indonesian products in export destination countries. This is becoming increasingly relevant in the midst of global dynamics that show a shift in the procurement mechanism of vaccines towards a subregional and bilateral approach, as well as the increasing need for countries to strengthen the independence of vaccine production.
Bio Farma considers synergy with BPOM RI as an important step in strengthening Indonesia's position in the global health ecosystem. Through its long experience as a vaccine manufacturer, Bio Farma continues to support Indonesia's health diplomacy, including through the development of strategic cooperation with partner countries in the ASEAN region, Africa, the Middle East, and South Asia.
In line with this, Bio Farma also continues to strengthen international cooperation initiatives through capacity development, knowledge transfer, and exploration of technology cooperation with partner countries as part of Indonesia's contribution to supporting global vaccine security, especially in developing countries.
Through synergy between regulators, industry, and stakeholders, Bio Farma is committed to continue to provide safe, quality, and globally competitive Indonesian vaccine and biological products.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)
